Blueprint Medicines (BPMC) Q1 2019 Earnings Call Transcript

For BLU-667, we’ve reached enrollment targets for registration-enabling cohort in our Phase I ARROW trial for patients with previously treated RET-fusion non-small cell lung cancer and RET-mutant medullary thyroid cancer. Based on the early achievement of the enrollment target for the lung cancer cohort, we announced plans to accelerate an NDA submission into the first quarter of 2020. In addition, we’re pleased to have received our second Breakthrough Therapy Designation for BLU-667, this time for RET-fusion positive non-small cell lung cancer that has progressed following platinum-based chemotherapy. This broad second line indication excludes any requirement for prior PD or PD-L1 therapy and aligns with our initial registration strategy.

We also continued to advance our BLU-554 program for hepatocellular carcinoma under our collaboration with CStone Pharmaceuticals. In the first quarter, the Chinese health authorities cleared the IND, enabling us to bring our ongoing Phase I trial in patients with TKI naive HCC to China. This morning, we announced the first Chinese patient has been dosed in this trial. Finally, our BLU-782 program for fibrodysplasia ossificans progressiva continues to advance nicely.

Based on progress with the ongoing Phase I trial in healthy volunteers and input from clinical experts, we announced plans to pull forward the initiation of a Phase II trial in FOP patients into the fourth quarter of 2019. All together, these updates represent the acceleration of our clinical stage portfolio. And with the follow-on offering completed in April, we’ve strengthened our financial foundation to advance these programs and further expand our research pipeline. In addition to our planned NDA and MAA submissions for avapritinib, we anticipate several important near-term data milestones.

At the ASCO annual meeting in early June, we plan to present detailed registration data for avapritinib and PDGFRalpha and fourth-line GIST and updated results from the ARROW trial of BLU-667 in RET-altered lung cancer and medullary thyroid cancer. In addition, we plan to present updated data for our EXPLORER trial of avapritinib in advanced systemic mastocytosis at the European Hematology Society Congress, which is in mid-June. Across each of these data sets, we plan to share important updates on clinical efficacy, including the rate and duration of response and safety. As our clinical and regulatory teams continue to fire on all cylinders, we’re also rapidly building commercial capabilities.

Since coming onboard, Christy has put in place a commercial leadership team and is developing a clear strategy to guide our path forward. I’ll now turn the call over to Christy to share more details.

Christy Rossi — Chief Commercial Officer

Thanks, Jeff. It’s great to be with all of you this morning to share our initial thinking on how Blueprint Medicines will approach this exciting next step in our journey toward bringing these important therapies to the patients and healthcare providers who are waiting for them. About six months ago, I joined Blueprint Medicines to lead commercial efforts across our portfolio. Previously, I led the North American multiple sclerosis business unit at Sanofi Genzyme, where I oversaw all aspects of the franchise and successfully launched twomedicines in a crowded field with multiple other therapies.

At Sanofi Genzyme, my team introduced this franchise and designed the company as a leader in MS by building our organization and operations around the specific needs of patients and healthcare providers. A key example is the MS One to One program, which we created from the ground up to provide superior reimbursement and clinical support to MS patients and the broader community, partnering with the healthcare providers who worked so tirelessly on their behalf each day. This experience, among others at Sanofi Genzyme and at Biogen, taught me the importance of engaging with patients and healthcare providers deeply and directly to understand their perspective and address their unique needs. Ultimately, this customer-centric approach drives better patient outcomes.

Since joining Blueprint Medicines in October, I’ve focused on three priorities: first, engaging externally with key stakeholders and internally with our scientific and clinical teams; second, recruiting top talent to assemble a strong and diverse leadership team; and third, establishing our initial portfolio go-to-market strategy. As I’ve gotten up to speed, I’ve been impressed with the rigor of our science, the speed and impact of our clinical research, and the depth of our engagement with the communities we are working to serve, all of which provide a strong foundation for this next step in Blueprint Medicines’ evolution into a fully integrated biopharmaceutical company. In recent months, we’ve got onboard commercial and medical leadership to augment our strong existing team, with key hires focused on market access, sales, marketing and medical affairs in the U.S. and Europe.

I am thrilled with the team of highly experienced leaders we are assembling. Individuals have excelled in prior roles across a range of leading biopharmaceutical companies and who bring deep launch experience in oncology, rare disease and specialty therapeutic areas. With this team in place, we’re now building core capabilities and implementing commercial strategies to effectively deliver our medicines to patients. Under our 2020 Blueprint corporate strategy, we’ve announced plan to submit marketing applications for avapritinib and BLU-667 across multiple patient population.

Our commercial focus extends beyond launching a single therapy in a single indication to building the foundation for a portfolio of precision therapies across multiple disease areas. Over the next 12 to 18 months, we plan to launch two innovative therapies, spanning multiple indications and geographies. To do this effectively, we need to balance focus with scale. Our approach will address the unique needs of patients and healthcare providers in specific indications while also leveraging our portfolio to more effectively reach our customers.

Our planned commercial organization will seek to optimize the initial avapritinib and BLU-667 launches in the U.S. while delivering core capabilities globally to build the foundation for long-term growth. The strategy we are using to create our field organization is an example of this balance between focus and scale. As we’ve considered different approaches, we’ve analyzed available data to define populations of treating healthcare providers and to better understand testing and prescribing behavior.

These analyses have resulted in important insights. One example is that about 80% of our target GIST healthcare provider accounts overlap with lung cancer accounts. This insight has informed our strategy to create a single oncology field team to focus on both GIST and lung cancer. With this approach, a targeted footprint to support the launch of avapritinib and PDGFRalpha and fourth-line GIST will also enable us to build the foundation for success in lung cancer.

Scientifically, clinically and commercially, we are focusing efforts on several core therapeutic areas, including GIST, lung cancer and systemic mastocytosis. As we continue to advance and expand development of avapritinib and BLU-667 across these areas, we are gaining new scientific and clinical insights, which we are using to continuously optimize our strategy. Similarly, in the commercial setting, we will gain critical experience as we initially bring avapritinib and BLU-667 to targeted patient populations. Through these first launches, we plan to generate awareness and understanding of the clinical data supporting our therapies, drive more effective patient identification and improve outcomes to increase testing, and work with stakeholders across the healthcare system to facilitate patient access.

We expect that this foundational work will enable us to realize the full potential of avapritinib and BLU-667 across a range of indications over the long term and reduce risk as we build our commercial organization. We recognize the importance of engaging patients, healthcare providers, payers and other stakeholders about the value our investigational medicines could provide to the healthcare system, especially within today’s evolving landscape. These efforts are now under way with the focus on obtaining insights from these stakeholders and creating dialogue around our approach. Fundamentally, we aim to deliver transformative therapies to rare, genomically defined patient populations with serious diseases and facilitate testing and research and new scientific innovations that will further improve care across our core therapeutic areas.

We believe these principles provide the context for a productive discussion on value and access. As I look ahead, I’m confident and incredibly excited about the impact Blueprint Medicines can make on patient care as we take this next step in our journey. I’ll now turn the call over to Mike to review our financial results for the first quarter.

Mike Landsittel — Chief Financial Officer

Thanks, Christy. Earlier today, we reported detailed first-quarter 2019 financial results in our press release. This morning, I’ll just touch on a few financial highlights from the quarter. First, we were very pleased to have closed a follow-on public offering in April that raised approximately $327.2 million in net proceeds to support the continued expansion and acceleration of our portfolio.

Combined with the $415.9 million in cash and investments at the end of the first quarter, our financial position is very strong ahead of key anticipated regulatory and commercial milestones. We expect that our cash and investments, including estimated net proceeds from our recent offering, but excluding any potential milestone payments under our existing collaborations, will be sufficient to fund our operations into the middle of 2021. By that time, avapritinib and BLU-667 could potentially be approved across multiple indications and geographies, putting us in a position to begin recognizing meaningful revenues. Second, as I’ve highlighted on past calls, we continue to see an incremental quarter-over-quarter increase in operating expenses.

In the first quarter, our total operating expenses increased by approximately $6.6 million compared to the fourth quarter of 2018. We expect a continued acceleration of quarter-over-quarter expense growth through the end of this year as we expand clinical development activities and build our commercial organization. In the second half of 2019, we plan to initiate new clinical trials for avapritinib in second-line GIST, BLU-667 in first-line lung cancer and BLU-782 in fibrodysplasia ossifcans progressiva. In addition, we’ll continue building commercial capabilities to support our planned avapritinib launch, including the hiring of field-based sales and medical affairs teams and the manufacturing of commercial drug supply.

Finally, before we move on to Q&A, I want to express our gratitude to all of the shareholders who participated in our April public offering. The offering proceeds further solidified our financial position, affording us the flexibility to continue to build the company for the long-term and focus our efforts on bringing the important new medicines to patients. I will now turn over to the operator for questions. Operator?

Questions & Answers:

Operator

Thank you. [Operator instructions] Our first question is from the line of Terence Flynn of Goldman Sachs. Your question, please.

Terence Flynn — Goldman Sachs — Analyst

Hi. Thanks for taking the question and congrats on all the progress. Maybe two for me. First, just on 667 and the ASCO data. Just wondering if it’s reasonable for us to assume that the durability of RET inhibitors generally will match that of the EGFR and ALK inhibitors.

Or is it possible that durability is going to differ by type of RET fusion? And then one on the commercial side. You mentioned balancing kind of focus with scale. Maybe help us think about the size of the footprint that you guys are considering. And then you’d talked a little bit about solid tumors and the overlap there, but help us think about the avapritinib for SM.

Would that require an incremental sales force build as well?

Jeff Albers — Chief Executive Officer

Terence, this is Jeff. I’ll start with the first one and then maybe ask Andy to chime in as well, and then I’ll turn it over to Christy to take your second question. So the first one is around BLU-667 data at ASCO and durability. I would just make the [Inaudible] given that we’re only a couple of weeks away from these ASCO — various ASCO presentations and then EHA presentation for systemic mastocytosis, we’re not going to comment or speculate on any of what data will be presented or how is that actually being worked on currently.

I would say more broadly though that where we sit today, we are very excited for a variety of reasons: first is, the data continues to mature very nicely; secondly, the enthusiasm of our ever-expanding global investigator group only seems to be increasing with the passage of time; and three, we continue to have very nice productive regulatory engagement within the program across various paths forward. And so we’re excited to see the Breakthrough Therapy Designation today, and we’re really looking forward to sharing more details at ASCO in a few weeks’ time. And on the second one, Christy, why don’t you in terms of size of footprint and then how we think about systemic mastocytosis and how that fits with solid tumors?

Christy Rossi — Chief Commercial Officer

Sure. We’re not going to guide at this point to a specific footprint in terms of the size of the sales force, but I’m happy to talk a little bit more about how we’re thinking about it. As I said, Blueprint is in a really fortunate position bringing our first therapy to patients and that we’re not just bringing one therapy to patients and one indication, but we have the benefit of potentially bringing two therapies in the U.S. over the next 12 to 18 months across a number of different patient populations.

And so that enables us to think about our commercial build in a different way. And that thinking really informs the plan to create an oncology focus field team, taking advantage of the natural overlap that we do see between prescribers who are treating these patient populations across a variety of settings. In terms of how we’re going to focus that team, initially, that team will very much be focused on centers of excellence, which is where we envision initial uptake will be happening for both avapritinib and BLU-667. But over time, we will also be engaging with community oncology practices, and having this type of structure will enable us to do that.

We think that’s really important because we want to make sure that we’re reaching those providers and patients, and we know that many patients are being treated at community oncology centers, and we want to make sure that they have the potential to benefit from both of these therapies as well. In terms of SM, again, we’re thinking about this build in a holistic way and in a way that will allow us to be flexible and incorporate systemic mastocytosis as we proceed with our development there. I’m incredibly excited about the opportunity in SM, both advanced in the near term, and in ISM down the road, which, as I’ve learned more about it, has just really compelling need in that patient population and is reminiscent of some of the sort of rare more chronic therapies that I’ve worked in my previous lives. Our structure will allow us to incorporate — focus on SM.

The overlap there is probably going to be not quite as significant as we see in oncology. There certainly will be some as we think about our centers. But there’s aspects of SM that are going to be a little bit different. It does feel a little bit more like a rare disease where the focus will be around patient identification and facilitating diagnosis.

And so it’s premature at this point to comment specifically on what the field structure will look like there, but certainly the overall organization that we are building has the flexibility to incorporate it.

Operator

Your next question is from the line of Joseph Thome of Cowen and Company. Your question, please.

Joseph Thome — Cowen and Company — Analyst

Thanks for taking my questions and congratulations on the progress this quarter. Maybe just first one on avapritinib in advanced SM. At EHA, are you going to be able to give maybe an early look at some of the PATHFINDER data? Or will that be too premature? And on that submission, tell us a little bit about the kind of the direction that you’ve been given with the FDA in terms of how many patients you need from PATHFINDER and degree of follow-up. I saw on FDA, they say it’s essentially a 10-month follow-up period for the primary endpoint that started last year. So is it primarily you need a larger safety database? Or do you need some efficacy data as well before this FDA meeting?

Jeff Albers — Chief Executive Officer

So Andy, why don’t you take that question?

Andy Boral — Chief Medical Officer

Yes. So I’ll start with the anticipated presentation at EHA. So that will focus on the additional data from the Phase I EXPLORER study really with an emphasis on — which is the study that we’ve reported at ASH last year with an emphasis on really deepening responses and durability of responses. And we will continue to update on the patients with indolent SM that have been enrolled in that study.

We are — I think — we’re pulling those data together and look forward to the presentation at EHA. In terms of the regulatory path forward in advanced SM, with the Breakthrough Therapy Designation, that gives us regular ongoing interactions with FDA and then with the, really, very nicely maturing data in the study as far as we showed at ASH last year, we’re seeing our response rate of about 80% using very rigorous IWG response criteria in patients with very advanced disease. We see that this really is a remarkable data. So together, this is — this has given us confidence that we can submit an NDA based on complete data from the Phase I EXPLORER study, along with preliminary data from the PATHFINDER study.

Of course, that is a matter of ongoing conversation with the FDA, and we will map that — the details out over the coming months, but we are on track for our planned filing next year. Going back, you did ask about PATHFINDER at EHA, those [Inaudible] for EHA.

Joseph Thome — Cowen and Company — Analyst

All right. Great. Thank you so much.

Operator

The next question is from Michael Schmidt of Guggenheim Securities. Your question, please.

Charles Zhu — Guggenheim Partners LLC — Analyst

Good morning, guys. This is Charles Zhu on for Michael Schmidt. Congrats on the quarter. I have a few questions within the systemic mastocytosis, the first one being, could you just very quickly remind us how many SM patients — advanced SM patients there were in the U.S.

and provide any color what sources of data you’ve used to arrive at that number?

Christy Rossi — Chief Commercial Officer

Sure. I’ll take that. So we believe and we’ve communicated previously in our filings that there are approximately 2,600 advanced SM patients in major markets that includes the U.S., as well as EU5 and Japan. As you’ve probably seen through your experiences while anytime you’re working in new disease areas, the estimates around these patient populations are imprecise.

So we’ve looked at a number of data sources to arrive at that conclusion, but the actual number could be more or less and. Certainly, in markets where there have not been effective therapies available, often what we find is that when new therapies are brought to patients, that facilitates increased diagnosis and treatment of patients, which is a good thing for patients in the community. And we expect we may see a similar dynamic if we bring avapritinib forward. So we’ll learn more about what this market looks like as we bring avapritinib forward and make it available to patients.

Jeff Albers — Chief Executive Officer

This is Jeff. Maybe I’ll just add to the two points that Christy raised around the imprecision of the data and then the fact that systemic mastocytosis broadly has all the markings of a rare disease where, as effective therapy comes forward, you start to see more patients being identified. And so that only broadens that error bar. Maybe a third component is the fact that the more we learn, the more we’re convinced that systemic mastocytosis is really just a continuum of a disease rather than these distinct subtypes.

And distinguishing between an advanced SM patient or a smoldering SM patient or, in many cases, even an indolent systemic mastocytosis patient, who has very high symptom burden, is imprecise at best. That was well characterized by our ASH presentation, where in a study, among the world experts in advanced systemic mastocytosis, there are certainly numerous indolent systemic mastocytosis patients included in that study. So more broadly, we look at the whole group as around 20,000 patients in those major markets with that huge error bar that Christy highlighted already.

Charles Zhu — Guggenheim Partners LLC — Analyst

Got it. That makes sense. And then a bit more of a clinical question. How are you guys thinking about the potential implications around patient identification, diagnosis and duration of avapritinib therapy specific for these different types of patients with systemic mastocytosis with associated non-mast cell malignancy, for example, if you have a patient with an indolent SM but a severe non-mast cell malignancy or vice versa?

Jeff Albers — Chief Executive Officer

So Andy, why don’t you take that?

Andy Boral — Chief Medical Officer

Yes. So — I mean, actually, just carrying off what Jeff way saying, it is important, as you were alluding to, that mastocytosis is a complex disease. It covers a very broad spectrum of indolent to advanced. In the advanced setting, it can be associated with another hematologic neoplasm.

Actually, by definition, that would not be indolent disease, and those patients certainly can have progression of their associated mast cell — associated non-mast cell neoplasm. I think really importantly, as we’ve shown today that as these evolve from the EXPLORER study, we’re seeing profound activity across all of the subtypes of advanced systemic mastocytosis, the pure ASMs, aggressive systemic mastocytosis patients, the ASMs within associated heme neoplasm and they very, very aggressive mast cell leukemias. So based on the data so far, we really don’t see a distinction, and there is evidence — increasing evidence that actually the KIT mutation can be found in the other associated clonal disorder that’s associated with mastocytosis. It might be that in many cases, avapritinib is active in that — through that mechanism, and there may be other mechanisms as well by which these patients are doing well.

Charles Zhu — Guggenheim Partners LLC — Analyst

OK. That makes sense. And I have one more last housekeeping question, if you don’t mind. It looks like you’ve excluded AML high-risk MDS and Philadelphia chromosome-positive malignancies from the Phase I EXPLORER trial.

Are those patients eligible for Phase II PATHFINDER? And this is specific to associated to hematologic malignancies.

Andy Boral — Chief Medical Officer

Yes. So those patients are excluded from EXPLORER and will be from PATHFINDER as well, really, because they have an acute need for other therapies. So you just need to treat their AML or their high-risk MDS urgently with cytotoxic chemotherapy. So once that’s under control, they would be potentially candidates for the studies, but not until the aggressive malignancy is treated.

Charles Zhu — Guggenheim Partners LLC — Analyst

Got it. Thank you for taking the questions.

Operator

Thank you. Our next question is from the line of David Nierengarten of Wedbush Securities. Your question, please.

David Nierengarten — Wedbush Securities — Analyst

I have a couple. First off, with 667, if you could maybe discuss a little bit about your strategy for commercialization likely being your second to market little bit differentiated profile. Are there any lessons from other launches like [Inaudible] inhibitors that are leading you to a differentiated strategy there? And a quick one on FOP, if you are planning on combination studies if or when palovarotene is approved.

Jeff Albers — Chief Executive Officer

OK. So for the first question around commercial strategy for BLU-667, I’ll have Christy take that one. And then for the FOP combination strategy, Andy, I’ll have you take that second question.

Christy Rossi — Chief Commercial Officer

Thanks. So if you think about commercialization in a market where there’s multiple options, I start from the perspective that additional therapy options are a great thing for patients. So we welcome having multiple therapeutic options within this category available. I also think if you look at a number of analogs.

You mentioned palovarotene. You look at ALK as well. Having multiple options helps to really drive, I think, the adoption of precision strategies overall. And so we’ll expect that having many therapy options here is going to be a good thing for us and for the treatment of patients.

For me personally, as I commented in this space, I’ve worked in other specialty markets where there are multiple, many, many therapeutic options available and having brought products forward [Inaudible] to market, and one thing I’ve learned is that often what ends up differentiating a product over time is not immediately obvious when you first bring it forward. So real world experience, real world evidence, engagement with healthcare providers and patients in a very direct way, bringing forward a sense of urgency and responsiveness to how you engage with the company, all of these things can be incredibly important in terms of what happens over the long term. So when I look at the data, that is supporting BLU-667. At this point, I’m incredibly excited about the opportunity.

I think we potentially have a best-in-class product here, and I think we’ll see how things evolve as we bring it forward and gain experience in the market.

Andy Boral — Chief Medical Officer

David, it’s Andy. So turning to the BLU-782 or the ALK2 inhibitors that we’re developing in FOP. We are developing BLU-782 as a single agent therapy. It’s once daily oral medication.

It’s critical — I think the critical distinguishing aspect of BLU-782 is it is the only thing out there that potently and selectively inhibits ALK2, which is the fundamental driver of the disease. And we think that really will make it the backbone of therapy for fibrodysplasia ossificans progressiva. I think, certainly, as multiple drugs are developed for patients with FOP, which is a great thing, there could be in the future potential opportunities for combinations. And I think those are the things we’d have to explore.

I think it depends a lot on if and when palovarotene is approved, what the actual indication is. But I can imagine situations where patients are taking BLU-782, and if someone has a flare, they might — you might want to combine it with palovarotene. Ideally though, BLU-782 will prevent the flares in the first place.

Operator

Our next question is from the line of Andrew Berens of SVB Leerink. Your question, please.

Andrew Berens — SVB Leerink — Analyst

Thanks. Congrats, guys, on the progress. Let me practice my question by saying I know you’re not going to run the ASCO data. So this is more of a question about the profile of 667.

I think that the last thing that people are, I guess, a little concerned about is the tolerability profile at the higher doses, and some of that may come from an orphan designation of 667 as a JAK1, two agent in small cell cancer. How should we think about the activity of 667 versus 292 in that regard?

Jeff Albers — Chief Executive Officer

It’s Andy. I’ll take that question. So BLU-667 is a highly selective and potent RET inhibitor and clearly inhibits RET far in excess of any of the other potential targets. So we don’t really see that as being a major concern or issue.

We’re really — we’re very happy to see the evolving data with now response rates of about 60% in both previously treated small cell lung cancer and previously treated medullary thyroid cancer, again, showing that we see some more activity in two very different molecular settings in fusions, in point mutations, the fusions being the drivers of the lung cancer, the point mutations of the thyroid cancer. And also, I want to remind you that BLU-667 is unique in that it’s equipotent across all of the various fusions, point mutations, including the various forms of the gatekeeper mutation with 804, which we think could lead to very prolonged durations of response. Of course, the studies have been going on that long and that is data to be determined. We’ll certainly update the activity and safety data at ASCO, but we are confident that we have what could be a best-in-class compound.

Andrew Berens — SVB Leerink — Analyst

OK. And then just one more, I guess, on RET. We’ve seen some frontline approvals in subgroups of non-small cell lung cancer with a single-arm trial, full approval, not accelerated approval. And I was just wondering, with a similar prevalence to RET, why does it seem to be — and both, I think, you and LOXO have pointed to the frontline as needing a randomized trial.

Why would it be necessary in RET-driven tumors versus some of the other ones like ROS1?

Andy Boral — Chief Medical Officer

Yes. So I’ll take that. It’s Andy. Yes, certainly, we are actively looking at the most rapid and aggressive path forward to approval in frontline.

Lung cancer, we will continue to discuss the possible path forward with FDA. And I think conceivably, there might be an opportunity for an accelerated approval in frontline. The ROS1 is a very specific circumstance where Crizotinib has already had an approval in lung cancer and so that was a supplementary NDA. So every situation is a little different.

I think what we know is that even if we were to have a single-arm frontline approval in lung cancer in the U.S., there’s a very high likelihood that countries in Europe or other parts of the world would want a randomized study, and it’s also very valuable to show that you can — that your compound is better, your medicine is better than available standards of care. So for various reasons, we will proceed with the Phase III comparator study.

Andrew Berens — SVB Leerink — Analyst

OK. Have there been naive patients enrolled in the 667 trial already?

Andy Boral — Chief Medical Officer

Yes. We do have some naive patients.

Andrew Berens — SVB Leerink — Analyst

OK. Thank you.

Operator

Our next question is from the line of Arlinda Lee of Canaccord. Your question, please.

Ben Shim — Canaccord Genuity — Analyst

Good morning. This is Ben for Arlinda. Sorry, if this has been asked before, but for the upcoming GIST dataset at ASCO, will you be breaking out survival and response data between fourth line and PDGFR?

Andy Boral — Chief Medical Officer

It’s Andy. I’ll like that. So the ASCO presentation for GIST will really focus on the registration data from the NAVIGATOR study. So that will — which is our two groups, the PDGFRalpha, Exon 18 population, which is across all lines of therapy and the fourth line and beyond GIST population.

And we’ll update on response, duration. And really, we want to focus on the data that we expect to be in a potentially — in a potential label assuming a successful filing because we think it is an important opportunity to explain to the community more about the compound, more about avapritinib activity, safety. And so that will really be the focus of the presentation. And we look very much forward to updating at ASCO.

Jeff Albers — Chief Executive Officer

This is Jeff. As a clarification, they will be broken apart. You’ll be able to see them separately as well.

Ben Shim — Canaccord Genuity — Analyst

Awesome. Thanks so much. Just a quick follow-up on 667. Lung patients — how many patients do you think will be presented? And will you provide the durability of the [Inaudible] dose?

Jeff Albers — Chief Executive Officer

So this is Jeff. As I said in the opening comments, in terms of guiding to the specifics of any of our presentations at ASCO or EHA, we’re not going to go into those details. It’s only a few weeks away, but we think across the board each data set will — there’ll be a robust set of data being presented across a wide range of criteria and aspects of the clinical development plan.

Ben Shim — Canaccord Genuity — Analyst

Thanks so much.

Operator

The next question is from the line of David Leibowitz of Morgan Stanley. Your question, please.

David Lebowitz — Morgan Stanley — Analyst

Thank you very much for taking my question. Could you characterize the challenge between advanced systematic mastocytosis smoldering and indolent? And when do we see data for latter tumors? And I guess, what the path forward is there?

Jeff Albers — Chief Executive Officer

Thanks, David. This is Jeff. I’ll start and then maybe I’ll have Andy chime in as well. So systemic mastocytosis, again, it is a — there are various subtypes that Andy walked through a few moments ago in the advanced setting.

But we continue to really view this as a continuum of disease. I was fortunate enough to interview on a panel a patient from our compassionate use program earlier this week, a woman who has indolent systemic mastocytosis. But as she describes her patient journey and the impact on her life and the life of her children, it sounded like anything but indolent disease. I mean incredibly high symptom burden, clearly mass cell infiltration impacting regular organ function and variety of different organs, and we see that time and time again.

And I think if there was one way I would characterize any specific patient is they’re all unique. And sometimes you have an indolent patient with very high symptom burden. Sometimes you have an advanced systemic mastocytosis patient with low symptom burden. And as Andy highlighted in his summary of data, what has been strikingly compelling for us is the consistency of activity when you inhibit the D816V mutation, which is common for all of those patients.

And so we’ve, obviously, gotten multiple ongoing studies. We initiated our study focus on indolent systemic mastocytosis earlier this year, and we’ve guided to sharing data from the first part of that study by the end of this year. But we suspect this will play out over time as we get a better handle of which patients are — in which patient is a therapy like avapritinib appropriate within that continuum. And we’re also studying different doses, so we’ll get a better sense on what dose is right for which particular groups of patients.

So Andy, anything you…

Andy Boral — Chief Medical Officer

No. Maybe all I’d add to that is that — echoing Jeff’s pointing that indolent is a bit of a misnomer for that disease, as we’ve — we’re working with multiple investigators around the world really now and we see these patients. And its a bit of a different group than the advanced. These are — we’re talking to allergists and dermatologists and gastroenterologists, and they all really uniformly tell us that 50% or more of their patients they think are potentially good candidates for our clinical trial with avapritinib.

So we think there’s a real need that is not met with available therapies.

David Lebowitz — Morgan Stanley — Analyst

One additional question. On BLU-782, when you were beginning a trial in the fourth quarter, how does, I guess, your design plans get affected by what happens with palovarotene considering they’re probably going to have a submission in, in the third quarter?

Andy Boral — Chief Medical Officer

Yes. It’s Andy. I’ll like that. So of course, we were aware of palovarotene before we even initiated our 782 program.

They’ve been out there for a while. And their progress, I think, is in line with what we expected. It really doesn’t impact our clinical trial plans.

Jeff Albers — Chief Executive Officer

And this is Jeff. I’ll add there because, I think, Christy highlighted this nicely from a commercial perspective, but one of the foundational elements of Blueprint Medicines is if you create highly selective therapies, it opens up opportunities for combinations down the road. And so we see no impact on the near-term execution of our clinical trials. We think, as Andy said, that 782 could potentially serve as the backbone of therapy, and then we’ll look to explore potential for combinations further down the road.

David Lebowitz — Morgan Stanley — Analyst

Thanks for that.

Operator

[Operator instructions] Our next question is from Eun Yang of Jefferies. Your question, please.

Eun Yang — Jefferies — Analyst

Thank you. Questions on 667. So as you enroll more patients at the optimal 400 QD dosing, the response rate increased nicely from the dose escalation. So as you have more patients enrolled in the 400 milligram QD, would that be reasonable to expect that the response rate would be approaching close to 70%?

Jeff Albers — Chief Executive Officer

Eun, this is Jeff. I’ll take that one. As we’ve said in earlier answers to questions, given the proximity to the ASCO presentations, we’re not going to guide or speculate on what or how we’ll share that data. Obviously, we’ve now got it in hand based on data cuts.

So we’ll pull that together and really look forward to seeing all of you in a few weeks in Chicago.

Eun Yang — Jefferies — Analyst

OK. And then second question is, obviously, response rates are quite strong at 60% range, but as we have seen with targeted therapies, tumors eventually develop secondary mutations. So perhaps it is pretty premature to ask this question, but in patients who have been treated with 667, have you seen or identified some common secondary mutation sites that could help you guide to develop second-generation product?

Jeff Albers — Chief Executive Officer

So I’m going to have Andy take that. So the question is around 667. I think it’s really twofold, the response rate we’ve seen so far and maybe just highlight the second-line patients predominantly and then also resistent and how we would speculate that that could evolve.

Andy Boral — Chief Medical Officer

So as we’ve already said, we’re very happy with the evolution of the data over time, and you’ll see how — you’ll see more details at ASCO. We — basic concept of Blueprint really is to create targeted therapies for targeted patient populations. And a lot of — as you think about how we developed avapritinib, that can take the path of developing a compound that addresses mutations that are resistant to other therapies. So that’s an area that we’re very interested in.

We are doing — circulating tumor DNA sequencing on the blood samples from all of our patients, both at baseline and over the course of therapy, and it’s very important to understand the mechanisms of resistance. We think we are very well positioned to develop new compounds to address those mechanisms of resistance, but we haven’t disclosed any information about what they might be yet.

Eun Yang — Jefferies — Analyst

The last question. What’s the timing for starting Phase III in first-line RET-fusion non-small lung cancer? Thank you.

Jeff Albers — Chief Executive Officer

This is Jeff. So we’ve guided to that trial starting in the second half of this year.

Eun Yang — Jefferies — Analyst

Thank you.

Operator

And now I would like to turn the call back over to Jeff Albers.

Jeff Albers — Chief Executive Officer

Excellent. So thank you, operator, and thanks, everyone, for taking time to join us today and for your continued support of Blueprint Medicines. And as I mentioned, we look forward to seeing you all in ASCO in just a few short weeks. Thank you.

Bye-bye.

Operator

[Operator signoff]

Duration: 50 minutes

Call participants:

Kristin Hodous — Investor Relations, Blueprint Medicines

Jeff Albers — Chief Executive Officer

Christy Rossi — Chief Commercial Officer

Mike Landsittel — Chief Financial Officer

Terence Flynn — Goldman Sachs — Analyst

Joseph Thome — Cowen and Company — Analyst

Andy Boral — Chief Medical Officer

Charles Zhu — Guggenheim Partners LLC — Analyst

David Nierengarten — Wedbush Securities — Analyst

Andrew Berens — SVB Leerink — Analyst

Ben Shim — Canaccord Genuity — Analyst

David Lebowitz — Morgan Stanley — Analyst

Eun Yang — Jefferies — Analyst

More BPMC analysis

All earnings call transcripts

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

Motley Fool Transcribing has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.